Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03618550
Brief Title: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

First Submitted : July 30, 2018
First Submitted that Met QC Criteria : August 2, 2018
First Posted : August 7, 2018

Last Update Submitted that Met QC Criteria : April 18, 2019
Last Update Posted : April 19, 2019 (Estimate)